A Phase 3 interventional study of mRNA-1010 and Fluarix® in Seasonal Influenza, sponsored by ModernaTX, Inc.. Completed at 301 sites in 11 countries. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one has the largest enrollment, is the only one that started in 2024, is one of 4 in phase 3, and was the 10th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2021; this study’s year is marked. 1 started in 2024.
This study's enrollment of 40,805 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 471 across the 12 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
23 studies in Influenza, Human by Moderna, Inc.: 2 open now, 3 under way, 1 of them phase 3. Of 20 finished, 12 (60%) have results posted.
Among the 23 studies in Influenza, Human by Moderna, Inc., this one has the largest enrollment, is one of 3 that started in 2024, is one of 7 in phase 3, and was the 18th registered.
Moderna, Inc.’s Influenza, Human studies by the year they started, since 2015.
1 of the studies testing mRNA-1010 influenza vaccine in Influenza, Human that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, from their registry updates:
Among Moderna, Inc.’s 23 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants who are assigned female at birth or can become pregnant are eligible to participate if:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single injection of mRNA-1010 on Day 1.
Biological: mRNA-1010
Participants will receive a single injection of active comparator trivalent influenza vaccine (TIV) or quadrivalent influenza vaccine (QIV) (Fluarix®, Fluarix Tetra, Influsplit® Tetra, Alpharix® Tetra) on Day 1.
Biological: Fluarix® · Biological: Influsplit® Tetra · Biological: Fluarix Tetra · Biological: Alpharix® Tetra
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Day 7
Number of Participants With Unsolicited Adverse Events (AEs)
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Day 28
Number of Participants With Medically Attended AEs (MAAEs), AEs Leading to Study Discontinuation, SAEs, or Adverse Events of Special Interests (AESIs)
MAAEs were AEs that led to an unscheduled visit to a healthcare provider. SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Day 1 up to Day 181
Number of Participants With First Episode of Reverse Tanscription Polymerase Chain Reaction (RT-PCR) Confirmed Protocol Defined Influenza-like Illness (ILI) Caused by Any Influenza A or B Strains
Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2 degrees celsius \[°C\] \[\>99.0 degrees Fahrenheit {°F}\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing).
Time frame: Day 14 up to end of influenza season (up to 7.5 months)
Number of Participants With First Episode of RT-PCR Confirmed Modified United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains
Modified CDC-defined ILI: Body temperature ≥37.2°C (≥99.0°F) accompanied by cough and/or sore throat.
Time frame: Day 14 up to end of influenza season (up to 7.5 months)
Number of Participants With First Episode of RT-PCR-confirmed Protocol-defined ILI or Modified CDC-defined ILI Caused by Any Influenza A or B Strains With Antigenic Match to the Vaccine Strains
Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2°C \[\>99.0°F\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing). Modified CDC-defined ILI: Body temperature \>37.2°C (\>99.0°F) accompanied by cough and/or sore throat. The confirmed RT-PCR test of influenza A or B strains with antigentic match to the vaccine strains.
Time frame: Day 14 up to end of influenza season (up to 7.5 months)
Geometric Mean Titer (GMT) of Hemagglutination Inhibition (HAI)
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than upper limit of quantification (ULOQ) were converted to ULOQ. LLOQ = 10, ULOQ = 3620 for H1N1. LLOQ = 10, ULOQ = 2560 for H3N2. LLOQ = 10, ULOQ = 1356. 95% confidence interval (CI) was calculated based on the t-distribution of log-transformed values for geometric mean (GM) titer, then back transformed to original scale for presentation.
Time frame: Day 29
Number of Participants Reaching Seroconversion as Measured by HAI
Seroconversion was defined as either a Baseline HAI titer \<1:10 and a post-baseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in post-baseline HAI antibody titer. Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.
Time frame: Day 29
Number of Participants With an HAI Titer ≥1:40
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.
Time frame: Day 29
Geometric Mean Fold Rise (GMFR) of HAI Titers
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values for GM fold rise, then back transformed to the original scale for presentation.
Time frame: Baseline, Day 29
| Milestone | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Started | 20402 | 20403 |
| Received injection | 20349 | 20354 |
| Safety set | 20350 | 20353 |
| Per-protocol (pp) set | 20179 | 20124 |
| Solicited safety set | 3015 | 2997 |
| Pp immunogenicity subset (ppis) | 1167 | 1175 |
| Completed | 19568 | 19622 |
| Not completed | 834 | 781 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Death | 40 | 34 |
| Withdrew: Lost to follow-up | 435 | 420 |
| Withdrew: Physician decision | 42 | 25 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 261 | 255 |
| Withdrew: Randomized by mistake | 17 | 16 |
| Withdrew: Other than specified | 34 | 28 |
Solicited ARs were recorded daily using electronic diaries (eDiaries). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Note, not all solicited ARs were considered adverse events (AEs). Investigator reviewed whether the solicited AR was also to be recorded as an AE. A summary of all Serious Adverse Events (SAEs) and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | 2283 | 1400 |
An unsolicited AE was defined as any AE reported by the participant that was not specified as a solicited AR in the protocol. An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Number of Participants With Unsolicited Adverse Events (AEs) | 1204 | 1167 |
MAAEs were AEs that led to an unscheduled visit to a healthcare provider. SAEs were AEs that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, a congenital anomaly or birth defect, or was a medically important event. AESIs were AEs (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program for which ongoing monitoring and immediate notification by the investigator to the Sponsor was required. A summary of all SAEs and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| MAAEs | 2509 | 2439 |
| AEs Leading to Study Discontinuation | 3 | 1 |
| SAEs | 455 | 392 |
| AESIs | 17 | 15 |
Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2 degrees celsius \[°C\] \[\>99.0 degrees Fahrenheit {°F}\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing).
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Number of Participants With First Episode of Reverse Tanscription Polymerase Chain Reaction (RT-PCR) Confirmed Protocol Defined Influenza-like Illness (ILI) Caused by Any Influenza A or B Strains | 411 | 577 |
Modified CDC-defined ILI: Body temperature ≥37.2°C (≥99.0°F) accompanied by cough and/or sore throat.
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Number of Participants With First Episode of RT-PCR Confirmed Modified United States (US) Centers for Disease Control and Prevention (CDC)-Defined ILI Caused by Any Influenza A or B Strains | 223 | 290 |
Protocol-defined ILI: At least 1 systemic symptom (temperature \>37.2°C \[\>99.0°F\], chills, feverish, tiredness, headaches, or myalgia) and at least 1 respiratory symptom (sore throat, cough, sputum production, wheezing, or difficulty breathing). Modified CDC-defined ILI: Body temperature \>37.2°C (\>99.0°F) accompanied by cough and/or sore throat. The confirmed RT-PCR test of influenza A or B strains with antigentic match to the vaccine strains.
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Protocol-defined ILI | 261 | 364 |
| Modified CDC-defined ILI | 143 | 198 |
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than upper limit of quantification (ULOQ) were converted to ULOQ. LLOQ = 10, ULOQ = 3620 for H1N1. LLOQ = 10, ULOQ = 2560 for H3N2. LLOQ = 10, ULOQ = 1356. 95% confidence interval (CI) was calculated based on the t-distribution of log-transformed values for geometric mean (GM) titer, then back transformed to original scale for presentation.
| titer | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Influenza A H1N1 Antibody | 146.15 ± 136.43 | 80.08 ± 74.98 |
| Influenza A H3N2 Antibody | 149.48 ± 140.19 | 92.60 ± 86.85 |
| Influenza B/ Victoria | 250.92 ± 237.83 | 149.64 ± 142.08 |
Seroconversion was defined as either a Baseline HAI titer \<1:10 and a post-baseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in post-baseline HAI antibody titer. Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Influenza A H1N1 Antibody | 642 | 318 |
| Influenza A H3N2Antibody | 710 | 480 |
| Influenza B/ Victoria | 526 | 232 |
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria.
| Participants | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Influenza A H1N1 Antibody | 1079 | 940 |
| Influenza A H3N2 Antibody | 1090 | 1008 |
| Influenza B/ Victoria | 1159 | 1151 |
Seasonal influenza A strains included H1N1 and H3N2 and seasonal influenza B strain included Victoria. 95% CI was calculated based on the t-distribution of the difference in the log-transformed values for GM fold rise, then back transformed to the original scale for presentation.
| ratio | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Influenza A H1N1 Antibody | 4.07 ± 3.84 | 2.24 ± 2.11 |
| Influenza A H3N2 Antibody | 4.70 ± 4.44 | 2.98 ± 2.81 |
| Influenza B/ Victoria | 3.14 ± 2.99 | 1.88 ± 1.80 |
Collected over All-cause mortality, SAEs, AESIs, MAAEs, and AEs led to study discontinuation: Day 1 up to Day 181. Non-serious AEs: up to 28 days after study injection, unless they met criteria for AESIs, MAAEs, or AEs led to study discontinuation.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mRNA-1010 | 40/20,402 (0.2%) | 455/20,350 (2.2%) | 0/20,350 (0%) |
| Licensed Inactivated Seasonal Influenza Vaccine | 34/20,403 (0.2%) | 392/20,353 (1.9%) | 0/20,353 (0%) |
| Event | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine |
|---|---|---|
| Cerebrovascular accidentNervous system disorders | 15/20350 | 13/20353 |
| Atrial fibrillationCardiac disorders | 14/20350 | 6/20353 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 14/20350 | 7/20353 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 6/8834 | 3/8720 |
| Cardiac failure congestiveCardiac disorders | 13/20350 | 6/20353 |
| DeathGeneral disorders | 12/20350 | 4/20353 |
| SepsisInfections and infestations | 7/20350 | 11/20353 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 10/20350 | 2/20353 |
| Acute myocardial infarctionCardiac disorders | 5/20350 | 10/20353 |
| Myocardial infarctionCardiac disorders | 9/20350 | 3/20353 |
Randomization set included all participants who were randomized, regardless of the participants' treatment status in the study. Participants were analyzed according to the treatment group to which they were randomized.
| Age, Continuous(years) | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine | Total |
|---|---|---|---|
| Mean | 64.2 ± 8.28 | 64.2 ± 8.36 | 64.2 ± 8.32 |
| Sex: Female, Male(Participants) | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine | Total |
|---|---|---|---|
| Female | 11545 | 11662 | 23207 |
| Male | 8857 | 8741 | 17598 |
| Ethnicity (NIH/OMB)(Participants) | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine | Total |
|---|---|---|---|
| Hispanic or Latino | 2151 | 2072 | 4223 |
| Not Hispanic or Latino | 17956 | 18029 | 35985 |
| Unknown or Not Reported | 295 | 302 | 597 |
| Race/Ethnicity, Customized(Participants) | mRNA-1010 | Licensed Inactivated Seasonal Influenza Vaccine | Total |
|---|---|---|---|
| Race — White | 16851 | 16853 | 33704 |
| Race — Black or African American | 2698 | 2706 | 5404 |
| Race — Asian | 499 | 483 | 982 |
| Race — American Indian or Alaska Native | 72 | 86 | 158 |
| Race — Native Hawaiian or Other Pacific Islander | 20 | 19 | 39 |
| Race — Multiple | 110 | 104 | 214 |
| Race — Other | 51 | 55 | 106 |
| Race — Unknown | 15 | 16 | 31 |
| Race — Not Reported | 86 | 81 | 167 |
Showing the first 100 of 301 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2024 to primary completion in Aug 2025, 11 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 11 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1010 influenza vaccine